These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 16012904)
21. Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter. Hohnloser SH; Connolly SJ; Crijns HJ; Page RL; Seiz W; Torp-Petersen C J Cardiovasc Electrophysiol; 2008 Jan; 19(1):69-73. PubMed ID: 18031520 [TBL] [Abstract][Full Text] [Related]
24. Dronedarone: a new antiarrhythmic agent for the treatment of atrial fibrillation. Garcia D; Cheng-Lai A Cardiol Rev; 2009; 17(5):230-4. PubMed ID: 19690474 [TBL] [Abstract][Full Text] [Related]
25. Acute in vitro effects of dronedarone, an iodine-free derivative, and amiodarone, on the rabbit sinoatrial node automaticity: a comparative study. Celestino D; Medei E; Moro S; Elizari MV; Sicouri S J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):248-57. PubMed ID: 17875953 [TBL] [Abstract][Full Text] [Related]
38. Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome. Riera AR; Uchida AH; Ferreira C; Ferreira Filho C; Schapachnik E; Dubner S; Zhang L; Moffa PJ Cardiol J; 2008; 15(3):209-19. PubMed ID: 18651412 [TBL] [Abstract][Full Text] [Related]
39. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Connolly SJ; Crijns HJ; Torp-Pedersen C; van Eickels M; Gaudin C; Page RL; Hohnloser SH; Circulation; 2009 Sep; 120(13):1174-80. PubMed ID: 19752319 [TBL] [Abstract][Full Text] [Related]